Cargando…
The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
BACKGROUND: The primary goal of current chemotherapy in hepatoblastoma (HB) is reduction of tumour volume and vitality to enable complete surgical resection and reduce risk of recurrence or metastatic disease. Drug resistance remains a major challenge for HB treatment. In some malignancies inhibitio...
Autores principales: | Lieber, Justus, Eicher, Carmen, Wenz, Julia, Kirchner, Bettina, Warmann, Steven W, Fuchs, Jörg, Armeanu-Ebinger, Sorin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176244/ https://www.ncbi.nlm.nih.gov/pubmed/21854558 http://dx.doi.org/10.1186/1471-2407-11-362 |
Ejemplares similares
-
The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015) -
The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
por: Baev, Denis V., et al.
Publicado: (2014) -
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013) -
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts
por: Eicher, C, et al.
Publicado: (2013) -
Successful Establishment of an Orthotopic Hepatoblastoma In Vivo Model in NOD/LtSz-scid IL2Rγnull Mice
por: Ellerkamp, Verena, et al.
Publicado: (2011)